IHL News: Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinic - 3rd Mar 2023, 11:30pm

annb0t

Top 20
Incannex Healthcare

Highlights:

Incannex has engaged Catalent for the development and cGMP manufacture of Incannex’s own psilocybin drug product. The psilocybin is designed for use in Incannex’s ongoing psilocybin-assisted psychotherapy “PsiGAD” clinical development program for generalised anxiety disorder and for potential future commercial use or supply as a cGMP pharmaceutical grade product. Development of the drug product includes generation of the necessary quality and...

>>> Read more: Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use
 
Top Bottom